Chronic Urticaria Or Hives-Pipeline Review, H1 2017

Chronic Urticaria Or Hives-Pipeline Review, H1 2017


  • Products Id :- GMDHC9231IDB
  • |
  • Pages: 52
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Chronic Urticaria Or Hives-Pipeline Review, H1 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Urticaria Or Hives-Pipeline Review, H1 2017, provides an overview of the Chronic Urticaria Or Hives (Dermatology) pipeline landscape.

Chronic urticaria also known as hives, are an outbreak of swollen, pale red bumps, patches, or welts on the skin that appear suddenly either as a result of allergies, or for other reasons. The main symptom is itchy rashes. Chronic urticaria occurs when histamine and other chemicals are released from under the skin's surface, causing the tissues to swell. Predisposing factors include stress, caffeine, warm temperatures, alcohol and insect bites and stings. Treatment includes antihistamines and corticosteroids.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Urticaria Or Hives-Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Urticaria Or Hives (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Chronic Urticaria Or Hives and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 4, 3, 3, 1 and 3 respectively.

Chronic Urticaria Or Hives (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Urticaria Or Hives (Dermatology).

The pipeline guide reviews pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Chronic Urticaria Or Hives (Dermatology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Chronic Urticaria Or Hives (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Urticaria Or Hives (Dermatology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Chronic Urticaria Or Hives (Dermatology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Chronic Urticaria Or Hives (Dermatology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Chronic Urticaria Or Hives-Overview

Chronic Urticaria Or Hives-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Chronic Urticaria Or Hives-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Chronic Urticaria Or Hives-Companies Involved in Therapeutics Development

Biofrontera AG

ELORAC Inc

Faes Farma SA

Genentech Inc

GlaxoSmithKline Plc

Glenmark Pharmaceuticals Ltd

J Uriach Y Compania SA

Mycenax Biotech Inc

Novartis AG

Panacea Biotec Ltd

Synermore Biologics Co Ltd

Chronic Urticaria Or Hives-Drug Profiles

BF-Derm-1-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bilastine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cetirizine hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cidoxepin hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GDC-0853-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GSK-2646264-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ligelizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omalizumab biosimilar-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rupatadine-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Chronic Urticaria Or Hives-Dormant Projects

Chronic Urticaria Or Hives-Discontinued Products

Chronic Urticaria Or Hives-Product Development Milestones

Featured News & Press Releases

Jan 25, 2017: Pediapharm Announces the Commercial Launch of Rupall (Rupatadine) in Canada

Dec 19, 2016: Aralez Announces Commercial Launch Of BLEXTEN In Canada

Nov 18, 2016: Taiho and Meiji Announce the Launch of Bilanoa Tablets 20 mg, an Oral Anti-allergy Drug in Japan

Sep 28, 2016: Taiho Pharmaceutical Receives Approval to Manufacture and Market Bilanoa Tablets, an Oral Anti-allergy Drug in Japan

Jul 22, 2016: Uriach receives Health Canada approval for rupatadine

Jul 21, 2016: Pediapharm Receives Health Canada Approval for Rupatadine

Apr 25, 2016: Aralez Receives Health Canada Approval For BLEXTEN

Nov 13, 2015: Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market TAC-202 (bilastine), an Oral Anti-allergy Drug in Japan

May 25, 2015: Bilastine in Japan: Phase III trials completed and ready for registration

Jul 09, 2012: Uriach Extends Collaboration With Hyphens On Rupafin Oral Solution

Jul 02, 2012: Faes Farma Receives Approval For Bilastine In Mexico

Jan 24, 2012: Faes Farma announces bilastine's launch in Brazil

Mar 29, 2011: Faes Farma markets bilastine under the brand Bilaxten in Spain

Dec 23, 2010: Faes Farma: Bilastine is Approved in Two Other Countries

Dec 02, 2010: Faes Farma: Bilastine is approved in eight european countries

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Figures

Number of Products under Development for Chronic Urticaria Or Hives, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

List of Tables

Number of Products under Development for Chronic Urticaria Or Hives, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Chronic Urticaria Or Hives-Pipeline by Biofrontera AG, H1 2017

Chronic Urticaria Or Hives-Pipeline by ELORAC Inc, H1 2017

Chronic Urticaria Or Hives-Pipeline by Faes Farma SA, H1 2017

Chronic Urticaria Or Hives-Pipeline by Genentech Inc, H1 2017

Chronic Urticaria Or Hives-Pipeline by GlaxoSmithKline Plc, H1 2017

Chronic Urticaria Or Hives-Pipeline by Glenmark Pharmaceuticals Ltd, H1 2017

Chronic Urticaria Or Hives-Pipeline by J Uriach Y Compania SA, H1 2017

Chronic Urticaria Or Hives-Pipeline by Mycenax Biotech Inc, H1 2017

Chronic Urticaria Or Hives-Pipeline by Novartis AG, H1 2017

Chronic Urticaria Or Hives-Pipeline by Panacea Biotec Ltd, H1 2017

Chronic Urticaria Or Hives-Pipeline by Synermore Biologics Co Ltd, H1 2017

Chronic Urticaria Or Hives-Dormant Projects, H1 2017

Chronic Urticaria Or Hives-Discontinued Products, H1 2017

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

Biofrontera AG, ELORAC Inc, Faes Farma SA, Genentech Inc, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, J Uriach Y Compania SA, Mycenax Biotech Inc, Novartis AG, Panacea Biotec Ltd, Synermore Biologics Co Ltd

select a license
Single User License
USD 2000 INR 140000
Site License
USD 4000 INR 280000
Corporate User License
USD 6000 INR 420000

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com